Sulma Mohammed was named co-leader of the University of Florida’s Health Cancer Center’s Cancer Control and Population Sciences research program. She will also serve as co-director of the NCI-funded Florida-California Cancer Research, Education and Engagement CaRE2 Health Equity Center.
José Larios, a transplant hematologist, joined The Barbara Ann Karmanos Cancer Institute as a member of the bone marrow and stem cell transplant and hematology oncology multidisciplinary teams at Karmanos. He specializes in treating leukemia and lymphoma blood cancers, including Hodgkin and non-Hodgkin lymphomas. He began seeing patients at the Karmanos Cancer Center in Detroit in August 2024.
Vice President Kamala Harris announced a final rule by the Consumer Financial Protection Bureau to remove medical debt from consumer credit reports. This rule will reduce the burden of medical debt and ensure that patients are not denied access to credit for home mortgages, car loans, or small business loans due to unpaid medical bills.
Becky Kamowitz was named executive director of the Skin Cancer Foundation, a national nonprofit organization that is committed to decreasing the incidence and mortality skin cancer through public education. Kamowitz has worked for the foundation for more than a decade and previously served as interim executive director and senior director of marketing communications.Â
Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics, a multidisciplinary initiative to advance scientific investigation, translational research, and clinical care approaches for patients with RAS-driven cancers.Â
A collaborative effort to eliminate cancer health disparities among African Americans and other underserved populations in the Washington, DC, area is being reignited at the Johns Hopkins Kimmel Cancer Center and the Howard University Cancer Center.
The University of Hawai‘i Cancer Center and the John A. Burns School of Medicine are forming Ka ʻUmeke Lama, an initiative to transform cancer care in Hawaiʻi and the Pacific.
In December, Congress failed to advance a bipartisan year-end health care package that would have made a big difference in the fight against cancer, according to the American Cancer Society Cancer Action Network.Â
The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.
The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.Â
